Evidence map›Paper›PMID 27579675›Full record

Trial reportPloS one2016

Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.

Toshihiro Yoneyama, Sumio Ohtsuki, Kazufumi Honda, Makoto Kobayashi, Motoki Iwasaki, Yasuo Uchida, Takuji Okusaka, Shoji Nakamori, Masashi Shimahara, Takaaki Ueno and 13 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. IGFBP-3 enhances irinotecan efficacy in colorectal cancerResearch in pharmaceutical sciences · 2026
    Article
  3. Catching pancreatic cancer early: Are we there yet?Journal of the National Cancer Center · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Proteomics in pancreatic cancer.Biomarker research · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 2 countries.

Toshihiro YoneyamaDivision of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Sumio OhtsukiDepartment of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kazufumi HondaDivision of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan.
Makoto KobayashiDivision of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan.
Motoki IwasakiDivision of Epidemiology, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan.
Yasuo UchidaDivision of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Shoji NakamoriDepartments of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital, National Hospital Organization, Osaka, Japan.
Masashi ShimaharaDepartment of Oral Surgery, Osaka Medical College, Osaka, Japan.
Takaaki UenoDepartment of Oral Surgery, Osaka Medical College, Osaka, Japan.
Akihiko TsuchidaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.
Naohiro SataDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Tatsuya IokaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
Yohichi YasunamiIslet Institute, Fukuoka University, Fukuoka, Japan.
Tomoo KosugeHepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Takashi KanedaDepartment of Radiology, Nihon University School of Dentistry at Matsudo, Chiba, Japan.
Takao KatoDepartment of Oral Implant, Nihon University School of Dentistry at Matsudo, Chiba, Japan.
Kazuhiro YagiharaDepartment of Oral Surgery, Saitama Cancer Center, Saitama, Japan.
Shigeyuki FujitaDepartment of Oral and Maxillofacial Surgery, Wakayama Medical University, Wakayama, Japan.
Wilber HuangAbnova, Taipei City, Taiwan.
Tesshi YamadaDivision of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan.
Masanori TachikawaDivision of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Tetsuya TerasakiDivision of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Tohoku University · JPNihon University · JPOsaka Medical and Pharmaceutical University · JPFukuoka University · JPJapan Agency for Medical Research and Development · JPJichi Medical University · JPKumamoto University · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPOsaka National Hospital · JPSaitama Cancer Center · JPTaipei National University of the Arts · TWTokyo Medical University · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is one of the most lethal tumors, and reliable detection of early-stage pancreatic cancer and risk diseases for pancreatic cancer is essential to improve the prognosis. As 260 genes were previously reported to be upregulated in invasive ductal adenocarcinoma of pancreas (IDACP) cells, quantification of the corresponding proteins in plasma might be useful for IDACP diagnosis. Therefore, the purpose of the present study was to identify plasma biomarkers for early detection of IDACP by using two proteomics strategies: antibody-based proteomics and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics. Among the 260 genes, we focused on 130 encoded proteins with known function for which antibodies were available. Twenty-three proteins showed values of the area under the curve (AUC) of more than 0.8 in receiver operating characteristic (ROC) analysis of reverse-phase protein array (RPPA) data of IDACP patients compared with healthy controls, and these proteins were selected as biomarker candidates. We then used our high-throughput selected reaction monitoring or multiple reaction monitoring (SRM/MRM) methodology, together with an automated sample preparation system, micro LC and auto analysis system, to quantify these candidate proteins in plasma from healthy controls and IDACP patients on a large scale. The results revealed that insulin-like growth factor-binding protein (IGFBP)2 and IGFBP3 have the ability to discriminate IDACP patients at an early stage from healthy controls, and IGFBP2 appeared to be increased in risk diseases of pancreatic malignancy, such as intraductal papillary mucinous neoplasms (IPMNs). Furthermore, diagnosis of IDACP using the combination of carbohydrate antigen 19-9 (CA19-9), IGFBP2 and IGFBP3 is significantly more effective than CA19-9 alone. This suggests that IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of IDACP patients.

Indexed as

ProteomicsAdultAgedBiomarkers, TumorCA-19-9 AntigenCarcinoma, Pancreatic DuctalChromatography, LiquidFemaleHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3MaleMass SpectrometryMiddle AgedNeoplasm ProteinsNeoplasm StagingBiomarkers, TumorCA-19-9 AntigenIGFBP2 protein, humanIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Neoplasm Proteins

Identifiers

PMID27579675
PMCPMC5007017
OpenAlexW2508920170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.